, WU NSG 552 Exam 3 Psychopharmacology - 2026/2027
Edition | 200 Verified Questions - 180 Questions with Answers
WU NSG 552 Exam 3 Psychopharmacology 2026-180 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for WU NSG 552 Exam 3 focuses on
psychopharmacology, covering the principles of pharmacodynamics and pharmacokinetics, major drug
classes, and their clinical applications in psychiatric care. It includes 200 verified questions with
detailed rationales, designed to reinforce critical thinking and ensure mastery of the subject. The
content is aligned with the latest 2026/2027 academic guidelines and evidence-based practices, making
it an essential resource for nursing students. Each question is crafted to mirror the format and difficulty
of the actual exam, providing a realistic practice experience.
Key Features:
Principles of psychopharmacology: pharmacodynamics, pharmacokinetics, and drug interactions
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: typical and atypical, including mechanism of action and side effects
Anxiolytics and hypnotics: benzodiazepines, non-benzodiazepines, and buspirone
Mood stabilizers: lithium, valproate, lamotrigine, and carbamazepine
Stimulants and non-stimulants for ADHD
Cognitive enhancers for dementia and Alzheimer's disease
Substance use disorder pharmacotherapy: nicotine, alcohol, opioid, and others
Special populations: pediatric, geriatric, pregnancy, and lactation considerations
Herbal and over-the-counter supplements with psychiatric implications
Patient education, adherence, and monitoring parameters
Legal and ethical considerations in prescribing psychotropic medications
Case-based clinical scenarios and application questions
Latest updates in psychopharmacology research and guidelines
Exam-taking strategies and test-taking tips
Rationales for correct and incorrect answers
Comprehensive coverage of all exam blueprint domains
Aligned with AACN and NONPF competencies
Updates for 2026:
- Updated to reflect the latest 2026/2027 clinical practice guidelines
- Incorporated new FDA-approved psychotropic medications and indications
- Enhanced rationales with evidence-based research and references
- Added more case-based questions to improve clinical reasoning
- Revised to align with the latest WU NSG 552 course objectives and exam blueprint
Abstract:
This exam preparation document for WU NSG 552 Exam 3 provides a rigorous and comprehensive review of
psychopharmacology, essential for advanced practice nursing students. It encompasses the foundational principles
of drug action, including receptor binding, dose-response relationships, and pharmacokinetic variations across
populations. The document systematically covers all major psychotropic drug classes, from antidepressants and
antipsychotics to mood stabilizers and stimulants, detailing their mechanisms, therapeutic uses, adverse effects,
and drug interactions. Special emphasis is placed on evidence-based prescribing, monitoring parameters, and
Page 1
,patient education. Additionally, the content addresses the nuances of psychopharmacology across the lifespan,
including pediatric, geriatric, and pregnant patients, as well as those with comorbid substance use disorders. Each
of the 200 questions is accompanied by a detailed rationale that explains both the correct and incorrect options,
fostering a deep understanding of the material. This resource is meticulously updated to reflect the latest
2026/2027 guidelines and is designed to ensure success on the exam and in clinical practice.
Keywords:
Psychopharmacology, Nursing exam prep, WU NSG 552, Verified answers, Rationales, 2026/2027, Advanced
practice nursing, Psychotropic medications
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. Rationales
include relevant pharmacological principles, clinical considerations, and evidence-based guidelines to enhance
learning and retention.
Compliance Checklist:
Aligned with the latest WU NSG 552 course syllabus and exam blueprint
Incorporates current 2026/2027 clinical practice guidelines
Includes 200 verified questions with accurate answers and rationales
Covers all major psychopharmacology topics and drug classes
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Principles of 1-20 Pharmacodynamics, pharmacokinetics, drug 10%
Psychopharmacology interactions, receptor theory
Antidepressants 21-50 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants, clinical use
Antipsychotics 51-80 Typical and atypical antipsychotics, 15%
mechanism, side effects, metabolic
monitoring
Anxiolytics and Hypnotics 81-100 Benzodiazepines, non-benzodiazepines, 10%
buspirone, insomnia management
Mood Stabilizers 101-120 Lithium, valproate, lamotrigine, 10%
carbamazepine, monitoring
Stimulants and ADHD 121-140 Methylphenidate, amphetamines, 10%
Medications non-stimulants, dosing, side effects
Cognitive Enhancers 141-155 Donepezil, rivastigmine, memantine, 7.5%
Alzheimer's treatment
Substance Use Disorder 156-170 Nicotine replacement, buprenorphine, 7.5%
Pharmacotherapy naltrexone, acamprosate, disulfiram
Special Populations 171-185 Pediatric, geriatric, pregnancy, lactation 7.5%
considerations
Clinical Application and Case 186-200 Case-based scenarios, patient education, 7.5%
Studies ethical and legal issues
Page 2
, Q1. A patient with treatment-resistant depression is currently on fluoxetine 40 mg
daily. After reviewing pharmacogenomic testing, the prescriber considers adding a
second agent. Which combination is most likely to result in a dangerous
pharmacodynamic interaction?
A. Fluoxetine + bupropion
B. Fluoxetine + mirtazapine
C. Fluoxetine + buspirone
D. Fluoxetine + trazodone
Correct Answer: D. Fluoxetine + trazodone
Rationale: Fluoxetine inhibits CYP2D6 and CYP3A4, and trazodone is metabolized by
CYP3A4, leading to increased trazodone levels and risk of QT prolongation and sedation.
Additionally, both drugs increase serotonin, raising the risk of serotonin syndrome.
Bupropion, mirtazapine, and buspirone are less likely to cause severe pharmacodynamic
interactions; bupropion is a CYP2D6 inhibitor but does not significantly affect serotonin,
and mirtazapine and buspirone have lower serotonergic synergy.
Why Wrong:
A - Bupropion does not significantly increase serotonin and is often used adjunctively
without causing serotonin syndrome.
B - Mirtazapine has a different mechanism (alpha-2 antagonism) and is a common
augmentation strategy with lower serotonin syndrome risk.
C - Buspirone is a partial 5-HT1A agonist and is generally safe with SSRIs, though it
can increase serotonin but less dangerously than trazodone.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q2. Which pharmacologic property most accurately distinguishes aripiprazole from a
typical first-generation antipsychotic like haloperidol?
A. High affinity for D2 receptors with rapid dissociation
B. Full agonism at 5-HT2A receptors
C. Low occupancy of D2 receptors at therapeutic doses
D. Selective antagonism at D3 receptors
Correct Answer: A. High affinity for D2 receptors with rapid dissociation
Rationale: Aripiprazole is a partial agonist at D2 receptors with relatively rapid
dissociation, which contributes to a lower risk of extrapyramidal symptoms and
hyperprolactinemia compared to haloperidol, a full antagonist with tight D2 binding.
Haloperidol does not have significant 5-HT2A agonism (it is an antagonist), and
aripiprazole's D2 occupancy is high at therapeutic doses, not low. D3 selectivity is not a
defining feature.
Why Wrong:
B - Aripiprazole is a partial agonist at 5-HT2A, not a full agonist; haloperidol is an
Page 3
Edition | 200 Verified Questions - 180 Questions with Answers
WU NSG 552 Exam 3 Psychopharmacology 2026-180 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for WU NSG 552 Exam 3 focuses on
psychopharmacology, covering the principles of pharmacodynamics and pharmacokinetics, major drug
classes, and their clinical applications in psychiatric care. It includes 200 verified questions with
detailed rationales, designed to reinforce critical thinking and ensure mastery of the subject. The
content is aligned with the latest 2026/2027 academic guidelines and evidence-based practices, making
it an essential resource for nursing students. Each question is crafted to mirror the format and difficulty
of the actual exam, providing a realistic practice experience.
Key Features:
Principles of psychopharmacology: pharmacodynamics, pharmacokinetics, and drug interactions
Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, and atypical antidepressants
Antipsychotics: typical and atypical, including mechanism of action and side effects
Anxiolytics and hypnotics: benzodiazepines, non-benzodiazepines, and buspirone
Mood stabilizers: lithium, valproate, lamotrigine, and carbamazepine
Stimulants and non-stimulants for ADHD
Cognitive enhancers for dementia and Alzheimer's disease
Substance use disorder pharmacotherapy: nicotine, alcohol, opioid, and others
Special populations: pediatric, geriatric, pregnancy, and lactation considerations
Herbal and over-the-counter supplements with psychiatric implications
Patient education, adherence, and monitoring parameters
Legal and ethical considerations in prescribing psychotropic medications
Case-based clinical scenarios and application questions
Latest updates in psychopharmacology research and guidelines
Exam-taking strategies and test-taking tips
Rationales for correct and incorrect answers
Comprehensive coverage of all exam blueprint domains
Aligned with AACN and NONPF competencies
Updates for 2026:
- Updated to reflect the latest 2026/2027 clinical practice guidelines
- Incorporated new FDA-approved psychotropic medications and indications
- Enhanced rationales with evidence-based research and references
- Added more case-based questions to improve clinical reasoning
- Revised to align with the latest WU NSG 552 course objectives and exam blueprint
Abstract:
This exam preparation document for WU NSG 552 Exam 3 provides a rigorous and comprehensive review of
psychopharmacology, essential for advanced practice nursing students. It encompasses the foundational principles
of drug action, including receptor binding, dose-response relationships, and pharmacokinetic variations across
populations. The document systematically covers all major psychotropic drug classes, from antidepressants and
antipsychotics to mood stabilizers and stimulants, detailing their mechanisms, therapeutic uses, adverse effects,
and drug interactions. Special emphasis is placed on evidence-based prescribing, monitoring parameters, and
Page 1
,patient education. Additionally, the content addresses the nuances of psychopharmacology across the lifespan,
including pediatric, geriatric, and pregnant patients, as well as those with comorbid substance use disorders. Each
of the 200 questions is accompanied by a detailed rationale that explains both the correct and incorrect options,
fostering a deep understanding of the material. This resource is meticulously updated to reflect the latest
2026/2027 guidelines and is designed to ensure success on the exam and in clinical practice.
Keywords:
Psychopharmacology, Nursing exam prep, WU NSG 552, Verified answers, Rationales, 2026/2027, Advanced
practice nursing, Psychotropic medications
Answer Format:
Each question is presented in a multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. Rationales
include relevant pharmacological principles, clinical considerations, and evidence-based guidelines to enhance
learning and retention.
Compliance Checklist:
Aligned with the latest WU NSG 552 course syllabus and exam blueprint
Incorporates current 2026/2027 clinical practice guidelines
Includes 200 verified questions with accurate answers and rationales
Covers all major psychopharmacology topics and drug classes
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Principles of 1-20 Pharmacodynamics, pharmacokinetics, drug 10%
Psychopharmacology interactions, receptor theory
Antidepressants 21-50 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants, clinical use
Antipsychotics 51-80 Typical and atypical antipsychotics, 15%
mechanism, side effects, metabolic
monitoring
Anxiolytics and Hypnotics 81-100 Benzodiazepines, non-benzodiazepines, 10%
buspirone, insomnia management
Mood Stabilizers 101-120 Lithium, valproate, lamotrigine, 10%
carbamazepine, monitoring
Stimulants and ADHD 121-140 Methylphenidate, amphetamines, 10%
Medications non-stimulants, dosing, side effects
Cognitive Enhancers 141-155 Donepezil, rivastigmine, memantine, 7.5%
Alzheimer's treatment
Substance Use Disorder 156-170 Nicotine replacement, buprenorphine, 7.5%
Pharmacotherapy naltrexone, acamprosate, disulfiram
Special Populations 171-185 Pediatric, geriatric, pregnancy, lactation 7.5%
considerations
Clinical Application and Case 186-200 Case-based scenarios, patient education, 7.5%
Studies ethical and legal issues
Page 2
, Q1. A patient with treatment-resistant depression is currently on fluoxetine 40 mg
daily. After reviewing pharmacogenomic testing, the prescriber considers adding a
second agent. Which combination is most likely to result in a dangerous
pharmacodynamic interaction?
A. Fluoxetine + bupropion
B. Fluoxetine + mirtazapine
C. Fluoxetine + buspirone
D. Fluoxetine + trazodone
Correct Answer: D. Fluoxetine + trazodone
Rationale: Fluoxetine inhibits CYP2D6 and CYP3A4, and trazodone is metabolized by
CYP3A4, leading to increased trazodone levels and risk of QT prolongation and sedation.
Additionally, both drugs increase serotonin, raising the risk of serotonin syndrome.
Bupropion, mirtazapine, and buspirone are less likely to cause severe pharmacodynamic
interactions; bupropion is a CYP2D6 inhibitor but does not significantly affect serotonin,
and mirtazapine and buspirone have lower serotonergic synergy.
Why Wrong:
A - Bupropion does not significantly increase serotonin and is often used adjunctively
without causing serotonin syndrome.
B - Mirtazapine has a different mechanism (alpha-2 antagonism) and is a common
augmentation strategy with lower serotonin syndrome risk.
C - Buspirone is a partial 5-HT1A agonist and is generally safe with SSRIs, though it
can increase serotonin but less dangerously than trazodone.
Reference: Stahl, S.M. (2026). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6
Q2. Which pharmacologic property most accurately distinguishes aripiprazole from a
typical first-generation antipsychotic like haloperidol?
A. High affinity for D2 receptors with rapid dissociation
B. Full agonism at 5-HT2A receptors
C. Low occupancy of D2 receptors at therapeutic doses
D. Selective antagonism at D3 receptors
Correct Answer: A. High affinity for D2 receptors with rapid dissociation
Rationale: Aripiprazole is a partial agonist at D2 receptors with relatively rapid
dissociation, which contributes to a lower risk of extrapyramidal symptoms and
hyperprolactinemia compared to haloperidol, a full antagonist with tight D2 binding.
Haloperidol does not have significant 5-HT2A agonism (it is an antagonist), and
aripiprazole's D2 occupancy is high at therapeutic doses, not low. D3 selectivity is not a
defining feature.
Why Wrong:
B - Aripiprazole is a partial agonist at 5-HT2A, not a full agonist; haloperidol is an
Page 3
